Inventor · disambiguated record
Robert Scott Pearsall
Also filed as: PEARSALL ROBERT · PEARSALL ROBERT S · PEARSALL ROBERT SCOTT
32 granted patents·27 pending applications·469 citations·filing 2007–2025
97Inventor score
Top patents by PatentIndex Score
59 records- 0199US8703927B2Isolated nucleotide sequences encoding GDF trapsSEEHRA JASBIR·Filed 2012·Granted Apr 22, 2014·57 cites·9 claims
- 0299US8216997B2Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activatorsSEEHRA JASBIR·Filed 2010·Granted Jul 10, 2012·100 cites·20 claims
- 0399US8058229B2Method of increasing red blood cell levels or treating anemia in a patientSEEHRA JASBIR·Filed 2009·Granted Nov 15, 2011·97 cites·28 claims
- 0498US10889626B2Combined use of GDF traps and erythropoietin receptor activators to increase red blood cell levelsACCELERON PHARMA INC·Filed 2020·Granted Jan 12, 2021·4 cites·25 claims
- 0598US10829532B2Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levelsACCELERON PHARMA INC·Filed 2020·Granted Nov 10, 2020·4 cites·24 claims
- 0698US8361957B2Isolated GDF trap polypeptideACCELERON PHARMA INC·Filed 2011·Granted Jan 29, 2013·42 cites·14 claims
- 0797US10377996B2Methods of identifying ActRIIB variantsACCELERON PHARMA INC·Filed 2016·Granted Aug 13, 2019·24 cites·11 claims
- 0897US10131700B2Methods for treating refractory anemia with ringed sideroblastsACCELERON PHARMA INC·Filed 2017·Granted Nov 20, 2018·20 cites·25 claims
- 0997US9932379B2Isolated nucleotide sequences encoding GDF trapsACCELERON PHARMA INC·Filed 2016·Granted Apr 3, 2018·19 cites·12 claims
- 1096US10689427B2Combined use of GDF traps and erythropoietin receptor activators to increase red blood cell levelsACCELERON PHARMA INC·Filed 2018·Granted Jun 23, 2020·7 cites·17 claims
- 1196US9505813B2Use of GDF traps to treat anemiaACCELERON PHARMA INC·Filed 2013·Granted Nov 29, 2016·20 cites·63 claims
- 1296US9439945B2Isolated nucleotide sequences encoding GDF trapsACCELERON PHARMA INC·Filed 2014·Granted Sep 13, 2016·18 cites·15 claims
- 1393US11028145B2ALK7:actriib heteromultimers and uses thereofACCELERON PHARMA INC·Filed 2019·Granted Jun 8, 2021·4 cites·23 claims
- 1493US10227393B2TGF-beta superfamily type I and type II receptor heteromultimers and uses thereofACCELERON PHARMA INC·Filed 2016·Granted Mar 12, 2019·9 cites·27 claims
- 1591US11279746B2ALK4:ActRIIB heteromultimers and uses thereofACCELERON PHARMA INC·Filed 2020·Granted Mar 22, 2022·2 cites·11 claims
- 1691US10738098B2ALK4:ActRIIB heteromultimers and uses thereofACCELERON PHARMA INC·Filed 2018·Granted Aug 11, 2020·6 cites·33 claims
- 1789US10906958B2TGF-beta superfamily type I and type II receptor heteromultimers and uses thereofACCELERON PHARMA INC·Filed 2019·Granted Feb 2, 2021·2 cites·4 claims
- 1889US8642031B2Antagonists of BMP9, BMP10, ALK1 and other ALK1 ligands, and uses thereofSEEHRA JASBIR·Filed 2009·Granted Feb 4, 2014·4 cites·13 claims
- 1989US8158584B2Pharmaceutical preparations comprising an ALK1-Fc fusion proteinGRINBERG ASYA·Filed 2009·Granted Apr 17, 2012·10 cites·18 claims
- 2088US8455428B2ALK1 receptor and ligand antagonist and uses thereofGRINBERG ASYA·Filed 2007·Granted Jun 4, 2013·8 cites·21 claims
- 2187US2024158468A1Tgf-beta superfamily type i and type ii receptor heteromultimers and uses thereofACCELERON PHARMA INC·Filed 2023·Application pending·0 cites
- 2286US10829533B2Combined use of GDF traps and erythropoietin receptor activators to increase red blood cell levelsACCELERON PHARMA INC·Filed 2020·Granted Nov 10, 2020·1 cites·27 claims
- 2386US10227392B2ALK7:ActRIIB heteromultimers and uses thereofACCELERON PHARMA INC·Filed 2016·Granted Mar 12, 2019·3 cites·29 claims
- 2486US10196434B2ALK4:ActRIIB heteromultimers and uses thereofACCELERON PHARMA INC·Filed 2016·Granted Feb 5, 2019·3 cites·31 claims
- 2584US2024309098A1Alk7 antagonists and uses thereofACCELERON PHARM INC·Filed 2024·Application pending·0 cites
- 2682US12258380B2ALK4:actriib heteromultimers and uses thereofACCELERON PHARMA INC·Filed 2022·Granted Mar 25, 2025·0 cites·20 claims
- 2782US9452197B2Antagonists of BMP9, BMP10, ALK1 and other ALK1 ligands, and uses thereofACCELERON PHARMA INC·Filed 2013·Granted Sep 27, 2016·2 cites·7 claims
- 2881US12144860B2ALK1 receptor and ligand antagonists and uses thereofACCELERON PHARMA INC·Filed 2021·Granted Nov 19, 2024·0 cites·6 claims
- 2979US10059756B2Compositions comprising ALK1-ECD proteinGRINBERG ASYA·Filed 2012·Granted Aug 28, 2018·3 cites·16 claims
- 3079US2025197469A1Alk4:actriib heteromultimers and uses thereofACCELERON PHARMA INC·Filed 2025·Application pending·0 cites
- 3178US12024563B2ALK7 antagonists and uses thereofACCELERON PHARMA INC·Filed 2021·Granted Jul 2, 2024·0 cites·12 claims
- 3278US11827689B2ALK7:ActRIIB heteromultimers and uses thereofACCELERON PHARMA INC·Filed 2021·Granted Nov 28, 2023·0 cites·21 claims
- 3378US2022098559A1Isolated gdf trap polypeptideACCELERON PHARMA INC·Filed 2021·Application pending·0 cites
- 3476US11162085B2Methods for treating anemia in a subject in need thereofACCELERON PHARMA INC·Filed 2020·Granted Nov 2, 2021·0 cites·27 claims
- 3576US2021253658A1Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levelsACCELERON PHARMA INC·Filed 2020·Application pending·0 cites
- 3674US2020165583A1Isolated gdf trap polypeptideACCELERON PHARMA INC·Filed 2019·Application pending·0 cites
- 3774US2022396607A1Tgf-beta superfamily type i and type ii receptor heteromultimers and uses thereofACCELERON PHARMA INC·Filed 2020·Application pending·0 cites
- 3873US11168311B2Methods for treating anemia in a subject in need thereofACCELERON PHARMA INC·Filed 2020·Granted Nov 9, 2021·0 cites·25 claims
- 3973US11155791B2Methods for treating anemia in a subject in need thereofACCELERON PHARMA INC·Filed 2020·Granted Oct 26, 2021·0 cites·26 claims
- 4071US2021388104A1Methods and compositions for modulating angiogenesis and pericyte compositionACCELERON PHARMA INC·Filed 2021·Application pending·0 cites
- 4168US2021207107A1Methods and compositions for treating ineffective erythropoiesisACCELERON PHARMA INC·Filed 2020·Application pending·0 cites
- 4267US2019218272A1Alk4:actriib heteromultimers and uses thereofACCELERON PHARMA INC·Filed 2019·Application pending·0 cites
- 4367US2022017600A1Methods and compositions for modulating angiogenesis and pericyte compositionACCELERON PHARMA INC·Filed 2021·Application pending·0 cites
- 4465US2017327800A1Methods and compositions for treating ineffective erythropoiesisACCELERON PHARMA INC·Filed 2017·Application pending·0 cites
- 4564US2013243743A1Methods and compositions for treating ineffective erythropoiesisACCELERON PHARMA INC·Filed 2012·Application pending·0 cites
- 4663US2020048355A1Alk7 antagonists and uses thereofACCELERON PHARMA INC·Filed 2019·Application pending·0 cites
- 4763US2017137791A1Methods and compositions for treating ineffective erythropoiesisACCELERON PHARMA INC·Filed 2017·Application pending·0 cites
- 4859US2017354731A1Alk1 receptor and ligand antagonists and uses thereofACCELERON PHARMA INC·Filed 2017·Application pending·0 cites
- 4959US2018179293A1Methods and compositions for modulating angiogenesis and pericyte compositionACCELERON PHARMA INC·Filed 2018·Application pending·0 cites
- 5059US2013344067A1Alk1 receptor and ligand antagonists and uses thereofGRINBERG ASYA·Filed 2013·Application pending·0 cites
Showing the top 50 of 59 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Robert Scott Pearsall files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →